DAIICHI SANKYO COMPANY, LIMITED

Inactive Instrument

Analyst Reco. Daiichi Sankyo Company, Limited Other OTC

Equities

DSNKY

US23381D1028

Analyst Reco.

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Jefferies Adjusts Daiichi Sankyo’s Price Target to 6,600 Yen From 5,600 Yen, Keeps at Buy	05-24	MT
Jefferies Adjusts Daiichi Sankyo’s Price Target to 5,600 Yen From 4,800 Yen, Keeps at Buy	02-21	MT
Jefferies Upgrades Daiichi Sankyo to Buy From Hold, Adjusts Price Target to 4,800 Yen From 4,300 Yen	12-04	MT
Jefferies Adjusts Daiichi Sankyo’s Price Target to 4,300 Yen From 3,900 Yen, Keeps at Hold	23/10/23	MT
Jefferies Downgrades Daiichi Sankyo to Hold From Buy, Adjusts Price Target to 1,900 Yen From 2,000 Yen	25/09/23	MT
Jefferies Adjusts Daiichi Sankyo’s Price Target to 4,800 Yen From 5,300 Yen, Keeps at Buy	13/07/23	MT
Jefferies Adjusts Daiichi Sankyo's Price Target to 5,300 Yen From 4,300 Yen, Keeps at Buy	14/12/22	MT
Japan's Nikkei snaps 5-day losing streak amid US rate caution	25/08/22	RE
MARKETSCREENER'S WORLD PRESS REVIEW : June 6, 2022	06/06/22
FTSE Flat, PMI Data Adds to Case for Another BoE Rate Increase	21/02/22	DJ
AstraZeneca-Daiichi Sankyo's Enhertu Improves Progression-Free Survival, Objective Response Rate in Brain Metastases Patients	10/12/21	MT
AstraZeneca : Daiichi Sankyo's Enhertu Shows 55% Tumor Response Rate in Lung Cancer Patients	20/09/21	MT
Japanese shares jump on Fed's growth view, rate pledge	18/03/21	RE
Daiichi Sankyo Company, Limited Announces New 12-Month Analysis Data from ETNA-AF Non-Interventional Study Show Low Bleeding and ICH Rates in Frail and Ageing AF Patients on LIXIANA	31/08/20	CI
Japanese stocks slip as economy shrinks at record rate on pandemic hit	17/08/20	RE
Astrazeneca and Daiichi Sankyo Company, Limited Announces ENHERTU (Fam-Trastuzumab Deruxtecan-Nxki) Significantly Improved Tumor Response Rate and Overall Survival in HER2-Positive Metastatic Gastric Cancer in Phase II Destiny-Gastric01 Trial	29/05/20	CI
Royal Philips : AstraZeneca raises sales forecast after second quarter cancer drug, China boost	25/07/19	RE

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Protect and grow your investments with the help of our experts

Securing my Investments

fermer